BridgeBio Pharma shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating and announced a price target of $44.
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma shares rose following Scotiabank's initiation of coverage with a Sector Outperform rating and a $44 price target.
October 16, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma shares increased after Scotiabank initiated coverage with a Sector Outperform rating and set a price target of $44.
The initiation of coverage by Scotiabank with a positive rating and a specific price target is likely to boost investor confidence, leading to a short-term increase in BBIO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100